PET在前列腺癌中的应用

李亚军; 白人驹; 高硕; 李亚军; 白人驹; 高硕

[1]

Oyama N,Akino H,Suzuki Y,et al.The increased accumulation of[¹⁸F] fluorodeoxyglucose in untreated prostate cancer.Jpn J Clin Oncol.1999,29(12):623-629.

[2]

Jadvar H,Pinski JK,Conti PS.FDG PET in suspected recurrent and metastatic prostate cancer.Oncol Rep,2003,10(5):1485-1488.

[3]

Jadvar H,Xiankui L,Shahinian A,et al.Glucose metabolism of human prostate cancer mouse xenografts.Mol Imaging,2005,4(2):91-97.

[4]

Hara T,Kosaka N,Kishi H.PET imaging of prostate cancer using carbon-11-choline.J Nucl Med,1998,39(6):990-995.

[5]

Sutinen E,Nurmi M,Roivainen A,et al.Kinetics of[¹¹C] choline uptake in prostate cancer:a PET stydy.Eur J Nucl Med Mol Imaging,2004,31(3):317-324.

[6]

Yoshida S,Nakagomi K,Goto S,et al.¹¹C-choline positron emission tomography in prostate cancer:primary staging and recurrent site staging.Urol Int,2005,74(3):214-220.

[7]

Breeuwsma AJ,Pruim J,Jongen MM,et al.In vivo uptake of[¹¹C] choline does not correlate with cell proliferation in human prostate cancer.Eur J Nucl Med Mol Imaging,2005,32(6):668-673.

[8]

Kotzerke J,Prang J,Neumaier B,et al.Experience with carbon-11choline positron tomography in prostate carcinoma.Eur J Nucl Med,2000,27(9):1415-1419.

[9]

de Jong IJ,Pruim J,Elsinga PH,et al.Preoperative staging of pelvic lymph nodes in prostate cancer by ¹¹C-choline PET.J Nucl Med,2003,44(3):331-335.

[10]

DeGrado TR,Coleman RE,Wang S,et al.Synthesis and evaluation of ¹⁸F-labeled choline as an oncologic tracer for positron emission tomography:initial findings in prostate cancer.Cancer Res,2001,61(1):110-117.

[11]

Kwee SA,Coel MN,Lim J,et al.Prostate cancer localization with 18fluorine fluorocholine positron emission tomography.J Urol,2005,173(1):252-255.

[12]

Schmid DT,John H,Zweifel R,et al.Fluorocholine PET/CT in patients with prostate cancer:initial experience.Radiology,2005,235(2):623-628.

[13]

Oyama N,Akino H,Kanamaru H,et al.¹¹C-acetate PET imaging of prostate cancer.J Nucl Med,2002,43(2):181-186.

[14]

Fricke E,Machtens S,Hofmann M,et al.Positron emission tomography with ¹¹C-acetate and ¹⁸F-FDG in prostate cancer patients.Eur J Nucl Med Mol Imaging,2003,30(4):607-611.

[15]

Kato T,Tsukamoto E,Kuge Y,et al.Accumulation of[¹¹C] acetate in normal prostate and benign prostatic hyperplasia:comparison with prostate cancer.Eur J Nucl Med Mol Imaging,2002,29(11):1492-1495.

[16]

Kotzerke J,Volkmer BG,Neumaier B,et al.Carbon-11 acetate positron emission tomography can detect local currence of prostate cancer.Eur J Nucl Med Mol Imaging,2002,29(10):1380-1384.

[17]

Nunez R,Macapinlac HA,Yeung HW,et al.Combined ¹⁸F-FDG and ¹¹C-methionine PET scans in patients with newly progressive metastatic prostate cancer.J Nucl Med,2002,43(1):46-55.

[18]

Toth G,Lengyel Z,Balkay L,et al.Detection of prostate cancer with ¹¹C-methionine position emission tomography.J Urol,2005,173(1):66-69.

[19]

Larson SM,Morris M,Gunther I,et al.Tumor localization of 16β-¹⁸F-fluoro-5α-dihydrotestosterone versus ¹⁸F-FDG in patients with progressive,metastatic prostate cancer.J Nucl Med,2004,45(3):366-373.

[20]

Dehdashti F,Picus J,Michalski JM,et al.Positron tomographic assessment of androgen receptors in prostatic carcinoma.Eur J Nucl Med Mol Imaging,2005,32(3):344-350.